Publication | Closed Access

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Tisotumab VedotinCervical CancerMetastatic Cervical CancerMedicineClinical TrialsPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyHealth Sciences